CIS Pharma attends EMSO sarcoma symposium in Milano

Milano, Italy, Monday February 3 to Wednesday February 5, 2020 - CIS Pharma attends the sarcoma symposium of the European Society for Medical Oncology, EMSO, in Milano. The event is [...]

CIS Pharma’s polymer-drug carriers successfully loaded with Lu-177 and In-111

Bubendorf, Switzerland, Wednesday, January 8, 2020 - In several laoding experiments Lutetium-177 and Indium-111 were loaded to CIS Pharma’s polymer-drug carriers, at high efficiency reates. Labeling density was close the [...]

CIS Pharma’s polymer-drug carriers to load radioisotopes show excellent performance in a multiparameter toxicity study

Bubendorf, Switzerland, Monday, December 9, 2019 - CIS Pharm has tested several of its new polymer-drug carriers to conjugate radionuclides in a multiparameter cytotoxicity study at Cyprotex, a CRO based [...]

CIS Pharma successfully conjugated a model antibody to its polymer-drug carrier comprising radioisotopes

Bubendorf, Switzerland, Friday, November 1, 2019 - Within the scope of the proof-of-concept study at the Paul Scherer Institute, a number of polymer-drug carriers enabling the conjugation of different amounts [...]

Actinium announces positive interim results of antibody-radionuclide conjugate Iomab-B pivotal trial

New York, USA, Monday, October 28, 2019 - Actinium Pharmaceuticals Inc. announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, an antibody-radionuclide conjugate, including feasibility and [...]

CIS Pharma initiates a proof of concept program for its novel polymer-drug carriers tailored to radioisotopes

Bubendorf, Switzerland, Wednesday, September 5, 2019 - CIS Pharma has signed a research agreement with the Paul Scherer Institute, Switzerland. The program comprises an invitro and invivo program for the [...]

FDA approves novel antibody-drug conjugate Polivy

Maryland, USA, Monday, June 10, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Polivy - polatuzumab vedotin-piiq, Roche - in combination with the chemotherapy bendamustine and [...]

CIS Pharma starts collaboration with the Paul Scherer Institute on antibody-radionuclide conjugates

Bubendorf, Switzerland, Thursday, November 22, 2018 - CIS Pharma has identified the group of Prof. Schibli and Dr. Behe from the Paul Scherer Institute, ETH,  as potential partners for its [...]

Nordic Nanovectors presents promising Phase 1 study results on its antibody-radionuclide conjugate Betalutin

Philadelphia, USA, Thursday, November 1, 2018 - Betalutin is an antibody-radionuclide conjugate, ARC, representing a combination of lilotomab for targeting CD37, a protein that specifically exists on the surface of [...]

Novartis successfully completes acquisition of Endocyte and its new antibody-radionuclide conjugate

Zurich, Switzerland, Thursday, October 18, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies [...]